Warrior Met Coal Closes in on IPO
It is surprising to see a coal company come forward and file to be publicly traded, considering the industry’s recent history.
All Work
Chris Lange
Cadence Bancorp Announces Potential Pricing for IPO
Cadence Bancorp intends to price more than 7 million shares in the range of $19 to $21 apiece in an initial public offering valued up to around $181 million.
Is This the Turnaround Paratek Has Been Looking For?
Shares of Paratek Pharmaceuticals saw a huge gain early on Tuesday after the company provided a critical update on its late-stage pneumonia trial.
Has Conn’s Got All Its Ducks in a Row?
Conn's reported better-than-expected fiscal fourth-quarter financial results before the markets opened on Tuesday.
Monday’s Biggest Winners and Losers in the S&P 500
April 3, 2017: The S&P 500 closed lower on the day, down 0.16% and 3.84 points to 2,358.87. Separately the DJIA closed down 0.06% on the day at 20,651.17, down approximately 12.05 points.
Everbridge Prepares for Secondary Offering
Everbridge has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its secondary offering.
Tocagen Announces Potential Pricing for IPO
Tocagen expects to price more than 7 million shares in the range of $10 to $12 apiece for an initial public offering valued up to about $100 million.
How This Snap Analyst’s Hold Rating Is Really a Long-Term Buy
One independent research firm thinks that Snap has the potential to put up a fight against the likes of Facebook or Twitter, but it may take some time.
Jefferies Even More Bullish on Top Banks
One key analyst thinks that first-quarter results from banks will not be mind-blowing, but instead believes estimates are still biased upward as more rate hikes get built in, deposit betas remain low and credit…
Cloudera Files for IPO
Cloudera has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Why NovoCure Shares Are Skyrocketing
NovoCure saw its shares skyrocket early on Monday after the firm provided an update for its late-stage cancer trial.
Why Analysts Are Staying Positive on Financials Despite the Pullback
Financial stocks have perhaps seen the biggest boom since the Trump rally started in late November. But is it safe to keep buying into these stocks now that the rally is seemingly subsiding?
Why Analysts Are Growing Much More Bullish on Oil & Gas Stocks
The question remains whether the recent oil price level will stick or even push higher. In fact, a few analysts think they have the answer, based on a few prevailing tailwinds, to where oil…
Cara Therapeutics Announces Pricing for Secondary Offering
Cara Therapeutics has priced more than 4 million shares of common stock at $18 per share in a secondary offering valued up to around $92 million.
How Akari Therapeutics Is Putting Itself on the Map
Shares of Akari Therapeutics saw a handy gain on Friday after the firm announced that the FDA granted a Fast Track designation for its treatment of paroxysmal nocturnal hemoglobinuria.
ELF Beauty Closes in on Secondary Offering
ELF Beauty has priced its more than 8.34 million shares at $27 apiece in a secondary offering valued up to nearly $259 million.
How BlackBerry Won Big in Q4
BlackBerry reported mixed fiscal fourth-quarter financial results before the markets opened on Friday.
Thursday’s Biggest Winners and Losers in the S&P 500
March 30, 2017: The S&P 500 closed higher on the day, up 0.29% and 6.95 points to 2,368.08. Separately the DJIA closed up 0.32% on the day at 20,726.33, up approximately 67.01 points.
SEC Issues Charges Against Pastor Defrauding Retirees
The SEC has announced fraud charges and an emergency asset freeze obtained against a Michigan-based pastor accused of exploiting church members, retirees and laid-off auto workers
Many Analysts Ratings and Target Changes Seen in Oil & Gas
Thursday’s top analyst upgrades, downgrades and initiations contained many individual stock calls. Also seen was an unusual number of changes in analyst ratings, targets and estimates in the energy sector.